Gabapentin (All indications)

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S10033
R36117		 Blotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Hypospadias 1st trimester retrospective cohort (claims database) exposed to other treatment, sick excluded Adjustment: No Controls: mixed indications 1.17 [0.14;9.57] C
excluded (control group) 		1/365   7/2,997 8 365
ref
S10034
R36140		 Blotière (Controls unexposed NOS) (Other indications), 2019 Hypospadias 1st trimester retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.53 [0.21;10.87] C 1/365   3,371/1,875,733 3,372 365
ref
S8493
R27901		 Morrow (Controls exposed to Lamotrigine, sick), 2006 Hypospadias/genitourinary tract defects 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 1.62 [0.09;29.34] C 0/31   6/647 6 31
ref
Total 2 studies 1.55 [0.31;7.89] 3,378 396
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Blotière (Controls unexposed NOS) (Other indications), 2019Blotière, 2019 1 1.53[0.21; 10.87]3,37236569%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Morrow (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 1.62[0.09; 29.34]63131%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.55[0.31; 7.89]3,3783960.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed NOS) (Other indications; 2: Controls exposed to Lamotrigine, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.55[0.31; 7.89]3,3783960%NABlotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.53[0.21; 10.87]3,372365 -NABlotière (Controls unexposed NOS) (Other indications), 2019 1 exposed to other treatment, sickexposed to other treatment, sick 1.62[0.09; 29.34]631 -NAMorrow (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 1.55[0.31; 7.89]3,3783960%NABlotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 2 All studiesAll studies 1.55[0.31; 7.89]3,3783960%NABlotière (Controls unexposed NOS) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 20.55.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 10033

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.53[0.21; 10.87]3,372365 -NABlotière (Controls unexposed NOS) (Other indications), 2019 1 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.31[0.24; 7.17]143960%NABlotière (Controls exposed to Lamotrigine, sick) (Other indications), 2019 Morrow (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0